Join Free
SI Premium
RSS Feeds
E-mail Alerts
Portfolio
Login
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Nova Mentis Life Sciences Corp
(OP:
NMLSF
)
0.0030
-0.0038 (-55.88%)
Streaming Delayed Price
Updated: 9:30 AM EDT, Sep 11, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
800
Open
0.0030
Bid (Size)
N/A (0)
Ask (Size)
N/A (0)
Prev. Close
0.0068
Today's Range
0.0030 - 0.0030
52wk Range
0.0068 - 0.0279
Shares Outstanding
N/A
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
Psyched: LSD For Major Depression, Canada's Psilocybin Macrodose Trial, Treatments For Multiple Sclerosis And More
April 24, 2023
LSD Trial Study Shows Potential For Major Depression Psychedelics biopharma company Mind Medicine Inc. (NASDAQ: MNMD) recently shared positive topline data from an advanced clinical trial of LSD as a...
Via
Benzinga
Psychedelics And The Spectrum: Groundbreaking Study Details How One Firm Approaches Autism
April 20, 2023
The partnership between contract research organization KGK Sciences Inc. and Nova Mentis Life Science Corp. (OTC: NMLSF) has started <
Via
Benzinga
Performance
YTD
-76.38%
-76.38%
1 Month
-58.33%
-58.33%
3 Month
-77.61%
-77.61%
6 Month
-75.21%
-75.21%
1 Year
-85.65%
-85.65%
More News
Read More
Psyched: Four New States With Reform Bills, Psilocybin For Genetic Disorders And Functional Neurological Disorder, Struggle For Access & More
February 21, 2023
Via
Benzinga
Health Canada Grants Exemption: Phase 2 Trial On Psilocybin For Genetic Disorder
February 14, 2023
Via
Benzinga
Nova Mentis Is Looking To Treat Autism With Psilocybin
April 07, 2022
Via
Benzinga
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
December 27, 2022
Via
Benzinga
Psyched: Fed Guidelines And Research Production Quotas, Protests In Canada, Cal's Decrim Project
December 06, 2022
Via
Benzinga
Psychedelic Partnership To Test Psilocybin For FXS In First Phase 2 Clinical Trial
November 30, 2022
Via
Benzinga
Psychedelics For FXS Symptoms: New Research Contract For Upcoming Phase 2 Clinical Trial
November 17, 2022
Via
Benzinga
Psyched: Autopsy Reveals Death By Ketamine, LSD-Like Drugs Without Hallucinations, DEA & Right To Try Psilocybin
September 30, 2022
Via
Benzinga
Magic Mushroom In A Pill? New Microdose Plans Enter Clinical Studies: Here's What Scientists Want To Learn
September 29, 2022
Via
Benzinga
Nova Mentis Psilocybin Microdose Capsule Formulation to be Submitted in Health Canada Phase 2A Clinical Trial Application
September 29, 2022
Via
Newsfile
New Batch Of Psilocybin Microdose Capsules Is Ready, Learn All The Details
September 17, 2022
Via
Benzinga
Nova Mentis Completes Production of Psilocybin Microdose Capsules
September 15, 2022
Via
Newsfile
More Patent Applications For Psilocybin: Learn About NOVA's Psychedelic Treatments For Neurological Diseases
June 16, 2022
Via
Benzinga
Psyched: Christie's Launches NFT Collection Supporting Psychedelic Science, Origin's Listing On CSE Gives Retail Investors Access To Private Companies
June 08, 2022
Via
Benzinga
Nova Mentis NM-1001 Psilocybin Compound Gets DEA Approval For Export, Here's What Happened
June 07, 2022
Via
Benzinga
Psyched: Psilocybin Therapy Effective After One Year, Cybin & Deepak Chopra, Enveric Psilocybin Cancer Study
February 22, 2022
Via
Benzinga
This Psychedelics Penny Stock Is Up 55% After Successful Study On Microdosing For Autism
February 16, 2022
Via
Benzinga
Wellbeing Digital Sciences' Integrated Approach Aims To Capture Emerging Mental Health Tech And Psychedelics Market
February 08, 2022
Via
Benzinga
Wellbeing Digital Sciences' Subsidiary KGK Science Forms Tactical Partnership With Nova Mentis
January 27, 2022
Via
Benzinga
Psyched: Detroit Decriminalizes Psychedelics, Compass To Study Psilocybin For PTSD, Filaments Gets First-Ever FDA Approval
November 08, 2021
Via
Benzinga
Exposures
Product Safety
Psyched: British PM Considers Psychedelics, New Partnership To Study Psilocybin For Autism, Compass Gets Another Patent
October 26, 2021
Via
Benzinga
Psyched: The 50 Publicly-listed Psychedelics Companies, Atai's New Subsidiary, PharmaTher Gets New Orphan Drug Designation
October 18, 2021
Via
Benzinga
There Are Now 50 Psychedelics Companies Listed In The U.S. - Here They Are
October 13, 2021
Via
Benzinga
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.